All News

Found 324 articles

• Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma

  12/28/2021

  Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATL).

• Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

  12/12/2021

  Epizyme, Inc. presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK®, a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide in patients with relapsed/refractory follicular lymphoma who have been treated with at least one prior systemic therapy, including patients who are rituximab-refractory and/or POD24.

• Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma

  12/11/2021

  Daiichi Sankyo Company, Limited announced that valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, demonstrated promising response rates in a pivotal phase 2 study in Japanese patients with relapsed/refractory adult T-cell leukemia/lymphoma.

• Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

  12/2/2021

  Epizyme, Inc. today announced that new data from across its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 to 14, 2021 in Atlanta, Georgia.

• Epizyme to Participate in Jefferies London Healthcare Conference

  11/12/2021

  Epizyme, Inc. today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcare Conference.

• Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/9/2021

  Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update

• Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 05, 2021

  11/5/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that the Company approved the grant of equity awards to a new employee with a grant date of November 1, 2021, as equity inducement awards outside of the Company’s 2013 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company.

• Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414

  11/4/2021

  Epizyme, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

• Epizyme Announces Date of Third Quarter 2021 Financial Results

  11/2/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call to discuss its third quarter 2021 financial results and provide a business update on Tuesday, November 9, 2021 at 8:30 a.m. ET.

• The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics

  10/18/2021

  Ascentage Pharma today announced that a research team has recently published a paper in the renowned Journal of Medicinal Chemistry demonstrating the highly promising therapeutic potential of the embryonic ectoderm development (EED) inhibitor, EEDi-5273

• Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  10/7/2021

  Epizyme today announced that the Company approved the grant of equity awards to a new employee with a grant date of October 1, 2021, as equity inducement awards outside of the Company’s 2013 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company.

• Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress

  9/14/2021

  Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that clinical data will be presented at the upcoming 2021 European Society of Medical Oncology Virtual Congress, taking place on September 16-21, 2021.

• Ribon Therapeutics Announces Key Management Promotions

  9/1/2021

  Ribon Therapeutics today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.

• Epizyme Announced Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  8/20/2021

  Epizyme today announced that the Company approved the grant of equity awards to two new employees with a grant date of August 16, 2021, as equity inducement awards outside of the company's 2013 Stock Incentive Plan and material to the employees’ acceptance of employment with the Company.

• Epizyme Announces CEO Succession

  8/9/2021

  Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies announced its Chief Executive Officer succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO.

• Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/9/2021

  Epizyme today reported its second quarter 2021 financial results and provided a business update.

• Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

  8/9/2021

  Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHMED Limited, announce a collaboration to research, develop, manufacture and commercialize TAZVERIK® in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

• HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

  8/9/2021

  HUTCHMED Limited and Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announce a collaboration to research, develop, manufacture and commercialize TAZVERIK® in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

• 

  BeiGene Builds New Site in New Jersey; MorphoSys Expands Boston Presence

  8/3/2021

  BeiGene is building a new research and development and manufacturing facility on a 42-acre campus in New Jersey, while MorphoSys is now growing its presence in the greater Boston area.

• Epizyme Announces Date of Second Quarter 2021 Financial Results

  8/3/2021

  Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m. ET.